LRMDA (leucine rich melanocyte differentiation associated) is essential for melanocyte differentiation and melanosome biogenesis. Mechanistically, LRMDA functions as a binding protein within the RAB32-LRMDA-Commander endosomal trafficking complex, where it simultaneously associates with the Commander assembly and active RAB32 to regulate melanosome formation and cellular pigmentation 12. This complex operates distinctly from the SNX17-Commander assembly, highlighting functional plasticity in organelle biogenesis pathways 1. LRMDA mutations cause oculocutaneous albinism type 7 (OCA7), a hereditary hypopigmentation disorder characterized by reduced skin, hair, and eye pigmentation accompanied by poor visual acuity 312. Disease-causing mutations uncouple RAB32 and Commander binding, establishing the molecular basis of OCA7 12. Beyond pigmentation, LRMDA variants show pleiotropic effects across metabolic and inflammatory phenotypes. Genome-wide association studies identify LRMDA variants associated with mild obesity-related diabetes subtype 4, age at onset in HNF1A-MODY 5, COPD subtype classification 6, and widespread pain in females 7. Additionally, LRMDA appears as a chr10 rearrangement partner in endometrial polyps 8, suggesting broader roles in cellular regulation beyond melanocyte-specific functions.